US 12,403,308 B2
Swallowable capsule and method for stimulating incretin production within the intestinal tract
Mir A. Imran, Los Altos Hills, CA (US); Mir Hashim, Fremont, CA (US); and Emily Arnsdorf, Mercer Island, WA (US)
Assigned to Alva Therapeutics, Inc., Milpitas, CA (US)
Filed by InCube Labs, LLC, San Jose, CA (US)
Filed on Dec. 7, 2023, as Appl. No. 18/532,183.
Application 14/179,215 is a division of application No. 12/849,574, filed on Aug. 3, 2010, granted, now 8,682,440, issued on Mar. 25, 2014.
Application 18/532,183 is a continuation of application No. 17/885,049, filed on Aug. 10, 2022, granted, now 11,872,396.
Application 17/885,049 is a continuation of application No. 16/552,570, filed on Aug. 27, 2019, granted, now 11,439,817, issued on Sep. 13, 2022.
Application 16/552,570 is a continuation of application No. 16/230,749, filed on Dec. 21, 2018, abandoned.
Application 16/230,749 is a continuation of application No. 15/971,810, filed on May 4, 2018, abandoned.
Application 15/971,810 is a continuation of application No. 15/485,031, filed on Apr. 11, 2017, granted, now 9,987,487, issued on Jun. 5, 2018.
Application 15/485,031 is a continuation of application No. 15/192,928, filed on Jun. 24, 2016, granted, now 9,643,005, issued on May 9, 2017.
Application 15/192,928 is a continuation of application No. 14/599,350, filed on Jan. 16, 2015, granted, now 9,403,002, issued on Aug. 3, 2016.
Application 14/599,350 is a continuation of application No. 14/273,917, filed on May 9, 2014, granted, now 8,958,879, issued on Feb. 17, 2015.
Application 14/273,917 is a continuation of application No. 14/179,215, filed on Feb. 12, 2014, granted, now 8,781,591, issued on Jul. 15, 2014.
Claims priority of provisional application 61/273,389, filed on Aug. 3, 2009.
Prior Publication US 2024/0100331 A1, Mar. 28, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61N 1/36 (2006.01); A61K 38/26 (2006.01); A61N 1/05 (2006.01); A61N 1/372 (2006.01); A61N 1/06 (2006.01)
CPC A61N 1/36007 (2013.01) [A61K 38/26 (2013.01); A61N 1/05 (2013.01); A61N 1/0507 (2013.01); A61N 1/0509 (2013.01); A61N 1/37217 (2013.01); A61N 1/06 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A system for stimulating incretin-producing cells (IP-cells) in an intestinal tract of a patient to secrete an incretin, the system comprising:
a device configured to travel through the intestinal tract and electrically stimulate the IP-cells at any location in the intestinal tract; and
a controller for delivering an electrical signal from the device to an intestinal wall proximate the device, wherein the electrical signal includes a waveform configured to electrically stimulate the IP-cells in the intestinal tract to secrete the incretin without causing a peristaltic contraction.